Literature DB >> 10648633

7- and 10-substituted camptothecins: dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7- and 10-substituents.

B Vladu1, J M Woynarowski, G Manikumar, M C Wani, M E Wall, D D Von Hoff, R M Wadkins.   

Abstract

7-Alkyl, 7-alkyl-10-hydroxy, 7-alkyl-10-methoxy, and 7-alkyl-10, 11-methylenedioxy analogs of camptothecin have been synthesized and evaluated for their ability to trap human DNA topoisomerase I in cleavable complexes. The 7-alkyl chain lengths varied linearly from methyl to butyl. The concentration required to produce cleavable complexes with purified topoisomerase I in 50% of the plasmid DNA (EC(50)) was reduced by 1 order of magnitude by the introduction of a 10-methoxy or 7-alkyl group compared with camptothecin. The EC(50) values were reduced by 2 orders of magnitude with a 10-hydroxy or 10, 11-methylenedioxy moiety compared with camptothecin. The steady-state EC(50) concentrations for all of the analogs tested were slightly dependent on substitution at the 7-position, but this dependence was least with the 10-methoxy series. The kinetics of the reversibility of the complexes formed with all analogs was only slightly influenced by the length of the 7-substitution, with the trend that ethyl or greater lengths led to slightly reduced rate constants for cleavable complex reversal. These results were also observed for DNA-protein cross-link formation by the analogs in isolated CEM cell nuclei. Our data indicate that in vitro cleavable complex stability, as determined by the apparent rate constants for complex dissociation, does not reflect the in vitro biological activity of these camptothecin analogs. However, complex stability in vivo may be important for the antitumor activity of the compounds.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10648633

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  5 in total

1.  A theoretical study of some new analogues of the anti-cancer drug camptothecin.

Authors:  Nihar R Jena; Phool C Mishra
Journal:  J Mol Model       Date:  2006-10-06       Impact factor: 1.810

2.  Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?

Authors:  Fengzhi Li; Xiang Ling; Danni L Harris; Jianqun Liao; Yuping Wang; David Westover; Guohui Jiang; Bo Xu; Patrick M Boland; Chunyang Jin
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

3.  The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode.

Authors:  Maris A Cinelli; Andrew E Morrell; Thomas S Dexheimer; Keli Agama; Surbhi Agrawal; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2010-06-20       Impact factor: 3.641

4.  P53 and p38 MAPK pathways are involved in MONCPT-induced cell cycle G2/M arrest in human non-small cell lung cancer A549.

Authors:  Chong Zhang; Hong Zhu; Xiaochun Yang; Jianshu Lou; Difeng Zhu; Wei Lu; Qiaojun He; Bo Yang
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-02       Impact factor: 4.553

5.  Development of an enzyme‑linked immunosorbent assay for camptothecin.

Authors:  Liting Yan; Xiang Nan; Cunzheng Zhang; Haifang Wang; Xiaoyan Huang; Jun Hu; Yingqian Liu
Journal:  Mol Med Rep       Date:  2019-06-05       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.